tirzepatide news 2025 Eli Lilly is considering offering more Zepbound doses in vials at lower cost March 16, 2025 - Origin

This class of drugs has also been found to lower the risk of cardiovascular disease and certain cancers

BPC-157 is better suited for chronic tendon injuries, gut healing, and situations where you want daily sustained signaling at a lower cost ($250/mo)

Contact your healthcare provider if bruising persists beyond one week, increases in size, or is accompanied by warmth, redness, or pus, as these may indicate infection

Canadian Employer Plans Covering GLP-1s for Weight Loss Have Nearly Doubled Data from the International Foundation of Employee Benefit Plans (IFEBP) 2025 Pulse Survey shows a significant shift in Canadian employer attitudes toward GLP-1 coverage: 31% of employer plans now cover GLP-1s for weight loss (up from 17% in 2024) 56% cover for diabetes only (down from 66% in 2024) 20% of diabetes-only plans are considering adding obesity coverage Provincial public drug plans still cover semaglutide only for type 2 diabetes not for weight loss

It reduces the effectiveness of white blood cells, impairs the complement system, and weakens the mucosal barriers that serve as the first line of defense against urinary pathogens

Eli Lilly and Novo Nordisk have built enormous momentum around Zepbound, Mounjaro, Wegovy and related products